RetinalGenix Technologies (RTGN) Retained Earnings (2020 - 2026)
RetinalGenix Technologies (RTGN) reported Retained Earnings of -$18.4 million for Q1 2026, down 14.88% on a YoY basis from -$21.6 million in Q1 2025, and down 217.35% sequentially from $15.7 million in Q4 2025.
RetinalGenix Technologies (RTGN) Retained Earnings (2020 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 7 years of Retained Earnings data on file, last reported at -$18.4 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 14.88% year-over-year to -$18.4 million; the trailing twelve-month figure through Mar 2026 stood at -$18.4 million (down 14.88% YoY), and the FY2025 full-year result was $15.7 million, up 201.61% from the prior year.
- Retained Earnings eased to -$18.4 million in Q1 2026, from $15.7 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $15.7 million in Q4 2025 to a low of -$18.4 million in Q1 2026.
- A 5-year average of -$5.8 million and a median of -$9.9 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings slumped 294.03% in 2022 and surged 246.47% in 2023, its largest moves.
- Tracing RTGN's Retained Earnings over 5 years: stood at $7.9 million in 2022, then grew by 22.07% to $9.7 million in 2023, then plunged by 259.04% to -$15.4 million in 2024, then surged by 201.61% to $15.7 million in 2025, then tumbled by 217.35% to -$18.4 million in 2026.
- Business Quant data shows RTGN's Retained Earnings at -$18.4 million in Q1 2026, $15.7 million in Q4 2025, and -$17.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -6.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -583.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -4.10 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 6.91 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 14.62 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 2.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -1.40 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 5.32 Bn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | -18.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.40 Mn |
| Dec 31, 2025 | 15.68 Mn |
| Sep 30, 2025 | -17.24 Mn |
| Jun 30, 2025 | -16.70 Mn |
| Mar 31, 2025 | -16.02 Mn |
| Dec 31, 2024 | -15.43 Mn |
| Sep 30, 2024 | -14.56 Mn |
| Jun 30, 2024 | 12.11 Mn |
| Mar 31, 2024 | -13.26 Mn |
| Dec 31, 2023 | 9.70 Mn |
| Sep 30, 2023 | -10.57 Mn |
| Jun 30, 2023 | -9.88 Mn |
| Mar 31, 2023 | 8.03 Mn |
| Dec 31, 2022 | 7.95 Mn |
| Sep 30, 2022 | -8.30 Mn |
| Jun 30, 2022 | -5.80 Mn |
| Mar 31, 2022 | -5.48 Mn |
| Dec 31, 2021 | 4.64 Mn |
| Sep 30, 2021 | 4.28 Mn |
| Dec 31, 2020 | -2.93 Mn |